The tweet was deleted by the author.
But we saved everything 🙂.
Invesco announced a partnership with AnthropicAI to connect its model portfolio and practice management capabilities to Claude, granting financial advisors enhanced support. The stock edges higher on the day, trading at $28.7.
Invesco announced on October 27, 2026, that it is working with AnthropicAI to integrate model portfolio and practice management capabilities into Claude for financial advisors. The collaboration brings together the company’s portfolio intelligence, model portfolios and practice management expertise to enhance advisor support. Invesco’s connector will also provide users with access to its research-based referral program, including personalized scripts, according to Stock Titan.
View post on X Loading...
Stoch RSI is in overbought territory, a stretched reading that limits room for further upside. Shares of Invesco have climbed above the MA-200 but remain below the MA-20 and MA-50, producing a split daily structure. The nearest support is the weekly low at $28.04. The price has moved higher in recent days even as the broader chart remains bearish.
Traders should watch for a close above $29.36 to confirm buyers are willing to follow through, or a drop below $28.04 to show the move is being faded. Stoch RSI remains overbought, suggesting limited room for additional gains. Even though there has been a sustained move higher with a firm trend over the past week, the outlook for the coming trading week assigns a 24% probability to further upside and a 76% chance of downside, with the expected trading range between $28.07 and $29.32. On the weekly chart the longer-term picture stays constructive.
Previously it was reported that Invesco shares faced sustained selling pressure, with technical indicators confirming a broad downside bias. The recent price recovery and integration with AnthropicAI add a new dimension, but with Stoch RSI stretched and the stock navigating a mixed technical structure, traders should closely monitor the $28.04 support for signs of reversal risk in the near term.